Mexiletine: Pharmacology and therapeutic use

@article{Manolis1990MexiletinePA,
  title={Mexiletine: Pharmacology and therapeutic use},
  author={Antonis S. Manolis and Thomas F. Deering and Josie Cameron and N. A. Markestes},
  journal={Clinical Cardiology},
  year={1990},
  volume={13}
}
Mexiletine is a Class IB antiarrhythmic which has basic and clinical electrophysiologic properties similar to lidocaine. Like other Class I antiarrhythmic agents, mexiletine blocks the rapid inward sodium current responsible for phase 0 of the action potential. It has been noted in the clinical electrophysiology laboratory to have minimal effect on sinus node function and AV nodal and His‐Purkinje system conduction. Pharmacokinetic studies have shown that oral absorption is rapid with… 

Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study

The treatment period following the mexiletine start was associated with a significant reduction of ventricular arrhythmias and the rate of side effects requiring dosage reduction or interruption was not neglectable.

Adverse Effects of Class I Antiarrhythmic Drugs

Several variations and interactions within a specific environment and underlying disorder might be of pharmacological or/and pharmacokinetic origin, making analysis of the true liability of the class I drugs very difficult when adverse effects occur.

Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies.

A retrospective review of a large skeletal muscle channelopathy patient cohort performed to address long-term safety and efficacy data outside a trial setting are lacking.

Slow kinetic property of mexiletine in guinea pig atrium.

It is concluded that mexiletine has a slow kinetic component as well as a fast one and may be more effective against the atrial arrhythmias than predicted previously.

A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T‐wave alternans in Timothy syndrome?

  • Gülhan Tunca ŞahinY. Ergul
  • Medicine
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  • 2018
This case presentation highlighted the use of mexiletine besides an initial beta‐blocker treatment in the cases with TS because the QTc interval shortened and T‐wave alternans disappeared.

Interactions of Rosiglitazone and Anti-Arrhythmic Drugs in Animal Model

The study concludes that PD activity of Rosiglitazone was not affected by the anti-arrhythmic drugs, and introduced a new statistical methodology for analyzing the blood glucose endpoint.

Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.

Mexiletine has no effect on the functional disability, impairment, survival, muscle cramp frequency and severity, and adverse events in ALS, but significant improvement in reducing muscle cramps severity and frequency was shown.

Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials.

Mexiletine has no effect on the functional disability, impairment, survival, muscle cramp frequency and severity, and adverse events in ALS, but significant improvement in reducing muscle cramps severity and frequency was shown.

References

SHOWING 1-10 OF 81 REFERENCES

Pharmacology and Clinical Use of Mexiletine

It suppresses chronic ventricular ectopy and is well tolerated in approximately two‐thirds of stable outpatients treated with this agent, and is comparable in efficacy to quinidine, procainamide and disopyramide in patients with refractory arrhythmias.

Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.

Mexiletine for ventricular arrhythmias.

Electrophysiological effects of mexiletine in man.

The results indicate that mexiletine shares some electrophysiological properties with procainamide and quinidine, when given to patients with conduction defects, and that the drug should not be used in patients with pre-existing impairment of impulse formation or conduction.
...